Harnessing the power of macrophages
Carisma’s innovative approach has the potential to create life-changing cellular therapies for patients with cancer and other serious disorders.
Learn MoreWe are leveraging the natural power of monocytes and macrophages by engineering them to attack tumors. CAR-Macrophages (chimeric antigen receptor macrophages) can eat away at tumors and lead to long-term anti-tumor immunity, giving patients a promising new long term strategy in the fight against cancer.
At Carisma, our pipeline includes multiple CAR-Macrophages designed to target solid tumors by engineering a patient’s own immune cells, giving hope to patients and their families.
If you or your family member would like more information, please learn more about our active and upcoming clinical trials.